<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01732991</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO 2012 - FB / PROPIL</org_study_id>
    <nct_id>NCT01732991</nct_id>
  </id_info>
  <brief_title>Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound</brief_title>
  <acronym>PROPIL</acronym>
  <official_title>Assessing the Impact of the Prostatic Photo-vaporization (PVP) With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PVP by Greenlight laser 180W is becoming a potential therapeutic alternative in the&#xD;
      treatment of benign prostatic hypertrophy (BPH) as recommended.&#xD;
&#xD;
      The PVP creates a prostatic box after the vaporization of the prostatic tissue of BPH. The&#xD;
      underlying prostatic tissue is the site of an ischemic necrosis secondary to the thermal&#xD;
      effects of proximity of the PVP. We intend to measure by prostatic MRI and contrast-enhanced&#xD;
      ultrasound the necrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The laser PVP with an optical fiber firing side carries out a vaporization of next prostatic&#xD;
      tissue and a necrosis of underlying prostatic tissue which corresponds to a postoperative&#xD;
      inflammatory area.&#xD;
&#xD;
      One of the side effects of this technique is the irritative syndrome which may involve&#xD;
      urinary frequency, urgency or burning urination in approximately 10 to 20% at 1 month.&#xD;
&#xD;
      The current literature does report neither the analysis of the underlying inflammatory&#xD;
      necrotic area in prostatic vaporized tissue, nor the analysis of the urinary irritative signs&#xD;
      post-laser PVP.&#xD;
&#xD;
      Progresses in the field of functional ultrasound imaging allow us to consider a study of&#xD;
      evolution of the underlying necrotic area devoid of micro-vascularisation under effect of PVP&#xD;
      laser. The parallel with results of MRI (radiological technique most referenced) during the&#xD;
      same period would help to support the experimental results of prostatic contrast-enhanced&#xD;
      ultrasound.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of thickness of the average necrotic area</measure>
    <time_frame>J0 (immediately after surgery) M1, M6 and M12</time_frame>
    <description>The primary outcome measure is the measurement of the thickness of the average necrotic area in millimeters on prostatic monitoring MRI and contrast-enhanced ultrasound (no hypothesis in this descriptive study). The variables will be collected immediately after surgery as well as M1, M6 and M12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of urinary irritative signs over 12 months</measure>
    <time_frame>J0, M1, M6 and M12</time_frame>
    <description>Evolution of urinary irritative signs over 12 months (prostatic monitoring MRI and contrast-enhanced ultrasound): score of IPSS questionary, results of the examination (binary variable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of prostatic volume over 12 months</measure>
    <time_frame>J0, M1, M6 and M12</time_frame>
    <description>Evolution of prostatic volume over 12 months (prostatic monitoring MRI and contrast-enhanced ultrasound)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Prostatic Hypertrophy, Benign</condition>
  <arm_group>
    <arm_group_label>prostatic photo-vaporization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>prostatic photo-vaporization (PVP) surgery with laser Greenlight</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>prostatic photo-vaporization (PVP)</intervention_name>
    <description>Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.</description>
    <arm_group_label>prostatic photo-vaporization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 40 years old without an upper age limit&#xD;
&#xD;
          -  Informed orally and in writing, having signed a consent which match to the research&#xD;
&#xD;
          -  Patient with a benign prostatic hypertrophy requiring surgical treatment by PVP&#xD;
&#xD;
          -  Person affiliated to a social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to MRI for patients with:&#xD;
&#xD;
               -  ocular metallic foreign object&#xD;
&#xD;
               -  any electronic medical device implanted by irremovable way (pacemakers,&#xD;
                  neuro-stimulator, cochlear implants ...)&#xD;
&#xD;
               -  metallic heart valve, old heart valves are specially an absolute contraindication&#xD;
                  because of risk of dysfunction&#xD;
&#xD;
               -  vascular clips implanted formerly on brain aneurysm&#xD;
&#xD;
          -  Allergy to Gadolinium&#xD;
&#xD;
          -  Contraindications to the contrast medium Sonovue:&#xD;
&#xD;
               -  Hypersensitivity to hexafluorinated sulphur or any other components of Sonovue&#xD;
&#xD;
               -  Recent acute coronary syndrome (within 6 months before the intervention)&#xD;
&#xD;
               -  Unstable ischemic heart disease (myocardial infarction being formed or evolving,&#xD;
                  typical angina of rest in the previous month)&#xD;
&#xD;
               -  Significant worsening of cardiac symptoms between the pre anaesthesia&#xD;
                  consultation and intervention&#xD;
&#xD;
               -  Recent intervention (less than 6 months) on coronary arteries or other factor&#xD;
                  suggesting clinical instability (changes in ECG, changes in clinical or&#xD;
                  biological parameters)&#xD;
&#xD;
               -  Acute heart failure or heart failure stage III or IV&#xD;
&#xD;
               -  Severe arrhythmias&#xD;
&#xD;
               -  Right-left shunt&#xD;
&#xD;
               -  Acute endocarditis&#xD;
&#xD;
               -  Valve prothesis&#xD;
&#xD;
               -  Severe pulmonary hypertension (pulmonary artery pressure &gt; 90mmHg)&#xD;
&#xD;
               -  Systemic hypertension uncontrolled&#xD;
&#xD;
               -  Respiratory distress syndrome&#xD;
&#xD;
          -  Prostatic biopsy &lt; 30 days or anal pathology&#xD;
&#xD;
          -  Patient with prostate cancer&#xD;
&#xD;
          -  Patient with a urinary infection&#xD;
&#xD;
          -  Patient with preoperative urinary catheter&#xD;
&#xD;
          -  Patient with a contraindication for surgery&#xD;
&#xD;
          -  Adult patient with a legal protection measure&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck BRUYERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU TOURS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>November 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2012</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatic Hypertrophy, Benign</keyword>
  <keyword>Greenlight laser</keyword>
  <keyword>Prostatic photovaporization</keyword>
  <keyword>Prostatic MRI</keyword>
  <keyword>Prostatic contrast-enhanced ultrasound</keyword>
  <keyword>Urinary irritative signs</keyword>
  <keyword>Postoperative necrotic area</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

